Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ciclesonide
Drug ID BADD_D00460
Description Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
Indications and Usage For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
Marketing Status approved; investigational
ATC Code R01AD13; R03BA08
DrugBank ID DB01410
KEGG ID D01703
MeSH ID C120481
PubChem ID 6918155
TTD Drug ID D0K7HU
NDC Product Code 70515-711; 53104-7633; 70515-712; 70515-701; 64918-1900; 24002-0016; 64918-1112; 70515-737
UNII S59502J185
Synonyms ciclesonide | (R)-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate | Alvesco | Omnaris
Chemical Information
Molecular Formula C32H44O7
CAS Registry Number 126544-47-6
SMILES CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sinus headache22.12.03.022; 17.14.01.002--
Sinusitis22.07.03.007; 11.01.13.005--
Skin lesion23.03.03.010--Not Available
Sneezing22.12.03.024--
Somnolence19.02.05.003; 17.02.04.0060.000834%
Sputum discoloured22.02.03.0100.000947%Not Available
Stress19.06.02.004--Not Available
Swelling08.01.03.015--Not Available
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.018--Not Available
Swollen tongue07.14.02.003; 10.01.05.015; 23.04.01.014--Not Available
Tachycardia02.03.02.0070.000379%Not Available
Throat irritation22.12.03.029; 07.05.05.0370.000379%Not Available
Tonsillitis22.07.03.008; 11.01.13.006--Not Available
Type I hypersensitivity10.01.03.006--Not Available
Ulcer08.03.06.001--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria10.01.06.001; 23.04.02.0010.000379%
Viral upper respiratory tract infection22.07.02.004; 11.05.04.007--Not Available
Vision blurred17.17.01.010; 06.02.06.0070.001023%
Visual impairment06.02.10.013--Not Available
Weight increased13.15.01.006--
Wheezing22.03.01.0090.001971%
White blood cell count increased13.01.06.013--Not Available
Seasonal allergy22.04.04.008; 10.01.04.001; 06.04.01.013--Not Available
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Osteopenia15.02.03.003; 14.04.04.004--Not Available
General physical health deterioration08.01.03.018--Not Available
Balance disorder08.01.03.081; 17.02.02.007--Not Available
Muscle strain15.05.07.002; 12.01.07.004--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages